We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Feedback Plc | LSE:FDBK | London | Ordinary Share | GB00BJN59X09 | ORD 50P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-10.00 | -7.14% | 130.00 | 125.00 | 135.00 | 140.00 | 125.00 | 140.00 | 22,878 | 14:00:27 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Electronic Computers | 1.03M | -2.92M | -0.2188 | -5.94 | 17.34M |
Date | Subject | Author | Discuss |
---|---|---|---|
17/5/2015 23:03 | this applies here RNS reach ie NON rnses to ramp the stock to mug punters before they are hit with a placing ny crony capitalist management who treat private investors/mug punters with contempt | the stigologist | |
15/5/2015 12:33 | Stig/21. The good thing about these BBs is the fact that they are an open forum for investors, traders and in fact anyone to comment on a particular share / company and generally it's great to get the mixed views of all involved. All I would add re: some of the comments in this board from yourselves is that: 1) the RNS re: share price movement has to be read in the context that any RNS that does not specify contract values and relate them to forecasts for the business are just business as usual. All the recent announcement are business as usual in some respect as they are a function of the company trading and undertaking business; they are not YET material with respect to orders etc and hence I understand why they released that statement although I agree that given their very small mcap and early start-up stature, the flurry of positive news does seem ironic / coincidental. 2) Let's not call others on this board liars or delve to similar levels. Go short if you think FDBK is all hot air. Anyway, enjoy the weekend all and let's all hope for further news. Nobby | norbert colon | |
15/5/2015 11:49 | Suit yourself. I doubt you guys were ever interested in investing here anyway. | lr2 | |
15/5/2015 11:47 | lol Another Rns. How many can a company issue around a no reason for rise warning ? | 21trader | |
15/5/2015 11:46 | Money agreed up front. If TexRAD deemed not worthy of follow up after research concluded then money is refunded otherwise goes towards first year's usage. | lr2 | |
15/5/2015 09:17 | how is a research agreement (IE you spend money suporting the research but get no cash back) money in the bank ? | the stigologist | |
15/5/2015 09:05 | AVO up 10%today another run back to 14p coming I prefer FDBK could perform well in the long term. | blueball | |
15/5/2015 08:57 | Each of these 'rampey NON RNS' releases is money in the bank and with 80% profit margin. Long may the 'rampey NON RNS' releases continue. | lr2 | |
15/5/2015 08:53 | another rampey NON RNS | the stigologist | |
15/5/2015 08:49 | Take the space out of the link if you want to see the original news item. It's an ADVFN thing - they won't allow competition links to be pasted here. investors.co.uk/comp Feedback (LON:FDBK), a medical imaging software firm, is teaming up with the University of Texas to examine the potential clinical application of the company’s TexRAD tumour-imaging technology. Specifically, experts in the MD Anderson Cancer Centre in Houston will look at how TexRAD derives ‘textures&rsqu The study will include around 400 patients, although the results will not be used to influence or guide the treatment regimes. Instead, the findings will help to strengthen the evidence base of TexRAD as an up and coming tumour texture heterogeneity analysis software. Prof. Haesun Choi, who will lead the study, said limitations of the size-based traditional evaluation of solid tumours have been well recognised. “More reliable user-friendly biomarkers that can reflect the tumour response and that can be used in risk-stratification are needed. “Analysing the tumour heterogeneity on CT images may provide insights of tumours that may be useful in evaluating the tumour response.” Earlier this week, Feedback signed a research agreement with the Oxford Stone Group at the University of Oxford & Oxford University Hospital NHS Trust. Under the deal, experts will investigate the potential future clinical application of Feedback's TexRAD on CT image data of patients with kidney stones. Feedback shares added 1% to 2.1p this morning. | lr2 | |
15/5/2015 07:03 | Another RNS. | blueball | |
14/5/2015 16:59 | Long term this will rocket | svenice7 | |
13/5/2015 06:49 | FDA approval will be important for Feedback, but the recent bunch of contract wins and collaborations suggests to me this company will build a global reputation on the back of Texrad anyway. It is a microcap, the market cap is still just £4.1m and already partnering with giants like Siemens. | kenwrong | |
12/5/2015 09:04 | Good summary sja FDA approval isn't the be all and end all. | blueball | |
12/5/2015 08:57 | In fairness and for clarity, this is the latest on FDA approval from interims in February: "TexRAD has been granted a European patent. The Group continues to make progress towards the launch later this year of a commercial version of its TexRAD software for the pharmaceutical trials market which is expected to be achieved following 21 CFR 11 self certification in the second quarter of 2015. We will continue to work with our distributor to gain momentum in this market. The FDA approval application for the Group's software systems has been a more difficult process than anticipated due to the new procedures. We anticipate that the application will be made during the second quarter of 2015" FDA approval is important, but not the be all and end all IMO...there is plenty of exposure outside of the FDA's remit, within Europe and the Far East... Plus...the software is already being used now in US for evaluating drug trials in colorectal cancers by Imaging Endpoints as has been previously announced..that looks like an important step towards FDA approval IMO All imo etc | sja123 | |
12/5/2015 08:43 | Exactly then you should not be suggesting anything. "which is not far away" | 21trader | |
12/5/2015 08:42 | Am I an insider I don't think I am I know no more than you do. | blueball | |
12/5/2015 08:37 | blueball How do you know FDA approval is not far away, are you a insider, do you know something others do not. Look at AGL they are still waiting far longer than anybody thought for their Rns on that not that it's damaging the price. | 21trader | |
12/5/2015 08:24 | Same report but different outlet...news getting around... | sja123 | |
12/5/2015 08:20 | "TexRAD can be integrated easily within existing hospital imaging systems without the need for any hardware modifications and can also be accessed via a pay-per-click service." | sja123 | |
12/5/2015 08:17 | and i doubt lawyers expert in FDA submissions come cheap ask AGL how much they have spent over last 5 years | the stigologist | |
12/5/2015 08:16 | nonsense and lies they will only START application "soon" FDA approval probably years away " The FDA approval application for the Group's software systems has been a more difficult process than anticipated due to the new procedures. We anticipate that the application will be made during the second quarter of 2015." | the stigologist |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions